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ABSTRACT
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for se-
lected hematological malignancies. Its curative potential is largely mediated by an immune-medi-
ated destruction of malignant cells by donor lymphocytes termed graft-versus-leukemia (GVL) ef-
fect. However, because of its toxicity, conventional allogeneic HSCT is restricted to younger and
fitter patients. These observations led several groups to set up new (less toxic) transplant protocols
(nonmyeloablative stem cell transplantation or NMSCT) based on a two-step approach: first, the
use of immunosuppressive (but nonmyeloablative) preparative regimens providing sufficient im-
munosuppression to achieve engraftment of allogeneic hematopoietic stem cells and, in a second
step, destruction of malignant cells by the GVL effect. Preliminary results showed that NMSCT
were feasible with a relatively low transplant-related mortality (TRM), even in patients older than
65 years. In addition, strong antitumor responses were observed in several hematological malig-
nancies as well as in some patients with renal cell carcinoma. After discussing the mechanisms and
efficacy of the GVL effect as well as the rationale for NMSCT strategies, this article reviews the
first results of ongoing clinical trials. Innovative modalities that may permit amplification of the
GVL effect while minimizing the risk of GVHD are discussed. Because the benefits of NMSCT over
alternative forms of treatment remain to be demonstrated, this strategy should be restricted to pa-
tients included in clinical trials.
243
INTRODUCTION
THE CURATIVE POTENTIAL of allogeneic hematopoieticstem cell transplantation (HSCT) is mediated not only
by the eradication of malignant cells by high-dose che-
motherapy (and total body irradiation), but also by an im-
mune-mediated graft-versus-leukemia (GVL) effect (1–5).
The power of the GVL effect and its apparent mediation
by donor lymphocytes led several groups to infuse donor
lymphocytes (DLI) in patients with relapsed leukemia af-
ter HSCT (6–12). The induction of durable remissions by
DLI demonstrated that the GVL effect is capable of erad-
icating hematological malignancies, even in the absence
of chemotherapy. This prompted the introduction of new
protocols based on the development of a GVL reaction af-
ter low-dose (less toxic) nonmyeloablative preparative reg-
imens providing sufficient immunosuppression to achieve
engraftment of allogeneic hematopoietic stem cells. Three
different approaches are currently investigated: purine ana-
log-based regimens (13–20), low-dose TBI followed by
mycophenolate mofetil (MMF) combined with cy-
closporine (CsA) (21–22), and a combination of cy-
clophosphamide, anti-thymocyte globulin (ATG) and
thymic irradiation (23,24) (Fig. 1).
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THE GVL EFFECT
The existence of a GVL effect in humans was first
demonstrated by the Seattle group, which showed a re-
duced relapse rate in patients with acute (2) and/or
chronic (3) GVHD. This was confirmed by other groups
who observed an increased risk of relapse after T cell-
depleted (TCD) allogeneic HSCT (4,25–27) as well as
after syngeneic HSCT (25). The GVL effect was also
demonstrated by the evolution of minimal residual dis-
ease post-transplantation, which often ceases to be de-
tectable only 6–12 months after HSCT (28) and by the
occurrence of GVL activity with or without GVHD after
cessation of GVHD prophylaxis for post-transplant re-
lapse (29–31).
Finally, the apparent power of the GVL effect and its
probable mediation by donor lymphocytes led several
groups to infuse DLI in patients with relapsed leukemia
after HSCT (6,8,9,12,32). The induction of durable re-
missions by DLI demonstrated that the GVL effect is ca-
pable of eradicating hematological malignancies even in
the absence of chemotherapy. DLI induce a complete re-
mission in about 65% of the cases in chronic myeloge-
nous leukemia (CML) and in 20–30% of the cases in
acute myeloid leukemia (AML) or myelodysplasic syn-
dromes (MDS) (12). In patients with CML, the response
rate is highest when lymphocytes are infused in early cy-
togenetic relapse (79%) and lowest in the accelerated
phase or blast crisis (19%) Table 1) (8,9,33). It has been
speculated that the better response of chronic-phase CML
may be explained by its low level of evolution and by
the fact that dendritic cells, the most potent antigen-pre-
senting cells, are part of the leukemic clone in CML (33)
and are capable of inducing a strong T cell response (34).
In contrast, the malignant cells present in accelerated-
phase CML or in acute leukemia may be less appropri-
ate antigen-presenting cells and may lead to the induc-
tion of anergy rather than an anti-leukemic T cell
response (35). Some patients with acute lymphoblastic
leukemia (ALL) (36), chronic lymphocytic leukemia
(CLL) (37), Hodgkin’s disease (38), lymphoma (39,40),
as well as multiple myeloma (MM) (41,42) have also re-
sponded to DLI or discontinuation of immunosuppres-
sive therapy. Finally, the GVL effect mediated by DLI
needs time: the median time to achieve a cytogenetic re-
mission was 85 (range 28–241) days for patients with
CML (the time to achieve molecular remission can be
prolonged) and 34 (range 16–99) days for patients with
AML (9).
Complications of DLI include acute and chronic graft-
versus-host disease (GVHD) and transient marrow apla-
sia. Acute GVHD occurs in about 60% of the patients
(grade 3 or 4 in about 20%) and is significantly corre-
lated with complete remission (9). Chronic GVHD also
occurs in about 60% of the patients (extensive in 30%)
and also correlates with response (9,43). However com-
plete remissions (CR) may be observed in the absence of
GVHD, suggesting that the GVL response may be inde-
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FIG. 1. Schedule of NMSCT. Pretransplant recipient immunosuppression is carried out with either (1) fludarabine-based non-
myeloablative conditioning regimen—Houston (13) and Jerusalem approaches (14); (2) low-dose TBI alone—Seattle approach
(87); (3) ATG, cyclophosphamide, and thymic irradiation (Rx)—Boston approach (24). Patients receive donor HSC on day 0.
Post-grafting immunosuppression is carried out with CsA6 methotrexate (MTX) for approaches 1 and 3 or with CsA 1MMF
for approach 2. DLI are given 30–100 days after the transplant in case of mixed chimerism and/or residual disease to obtain full
donor chimerism as well as eradication of tumor cells. ( s ) Cell of host origin; ( d ) cell of donor origin; (q ) tumor cell.
pendent of the clinical development of GVHD
(9,20,33,44). It is possible to reduce the risk of GVHD
without impairing the GVL effect by CD8 depletion of
DLI (11,44,45,48) or by starting with a low dose of T
cells and increasing the dose in a stepwise fashion in case
of no response (46,47).
In the European Group for Blood and Marrow Trans-
plantation (EBMT) study, survival after DLI for relapsed
CML was as good as that after transplantation: survival
probabilities for patients with hematological and cytoge-
netic relapses were 58% at 8 years and 80% at 6 years,
respectively (49). For AML, remissions of more than 2–4
years occurred (33). In the North American study, sur-
vival after DLI-induced remission of CML was 87%,
76%, and 73% at 1, 2, and 3 years, respectively (50). For
other diseases, survival probabilities at 1 and 2 years were
77% and 65%, respectively. However, unlike patients
with early-stage CML or AML, patients with MM do not
enjoy durable responses.
MHC-restricted CD41 and CD81 T cells, natural killer
(NK) cells, macrophages, as well as dendritic cells are
probably all involved in the process of both GVL and
GVHD (51–57). It is likely that cells implicated in the
GVL effect vary as a function of the hematologic ma-
lignancies involved, depending upon their major histo-
compatibility complex (MHC) expression (58) and the
nature of antigens presented. However, the time required
to achieve a clinical response after DLI suggests that a
specific response involving T cells and human leukocyte
antigen (HLA)-restricted antigens is important (35). Fi-
nally, the efficacy of CD8-depleted DLI (11,44,59) sug-
gests that CD41 cells are essential for the GVL reaction,
or that they recruit CD81 T cells in the patients.
DLI are associated with conversion from mixed
chimerism before infusion to complete donor hemato-
poiesis after DLI (9,44,46,60,61). Infusion of donor lym-
phocytes in patients who do not show donor hematopoi-
esis before DLI induces severe marrow aplasia that may
be resolved by the infusion of donor stem cells (8,33).
Moreover, DLI can displace residual host stem cells when
given for recurrence of nonmalignant diseases after allo-
geneic HSCT (62,63). In addition, donor-derived cyto-
toxic T cells (CTL) from allogeneic chimeras recognize
both normal and leukemic host hematopoietic cells
(64,65). Take together, these observations suggest that
the effect of DLI is probably directed against allo-spe-
cific antigens [such as minor histocompatibility antigens
(mHA)] rather than disease-specific targets. However,
aberrantly expressed or overexpressed cellular compo-
nents, such as proteinase 3 (66–68) or WT-1 (69), could
also be target antigens in the GVL effect.
A graft-versus-tumor (GVt) effect has also been dem-
onstrated in breast cancer and in renal cell carcinoma,
and possibly in ovarian (70) and non-small cell lung car-
cinomas (71) (Table 1). Tumor regression associated with
acute GVHD has been reported in patients receiving an
allogeneic HSCT for metastatic breast cancer (72,73).
Moreover, mHA-specific as well as MHC class I anti-
gen-specific CTL recognizing breast carcinoma target
cells were isolated from the blood of one such patient
(72). Simultaneous GVt and GVL effects were reported
after allo-HSCT and DLI in a patient with concurrent
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TABLE 1. EVIDENCE FOR GVL AND GVt EFFECTS
Response to DLI
Malignancy (reference) CR (%) Other evidence
CML (12,16,25) 64 Increased risk of relapse after T cell-depleted HSCT, reduced




AML (12,25) 20 Increased risk of relapse with identical twin HSCT, reduced
risk of relapse in patients with GVHD, efficacy of NMSCT
MDS (12,16) 38 Efficacy of NMSCT
ALL (12,25) 10 Reduced risk of relapse in patients with GVHD
MM (12,16) 29 Efficacy of NMSCT
NHL (12,15) 13 Efficacy of NMSCT
HD (181) NR (PR reported) Efficacy of NMSCT
CLL (15,37) Yes (low numbers) Efficacy of NMSCT
Breast cancer (72,143) NR Tumor response during acute GVHD, efficacy of NMSCT
Renal cell carcinoma (16) NR Efficacy of NMSCT
Melanoma (16) NR Occasional response after NMSCT
Ovarian cancer (70) NR Tumor response during acute GVHD
NR, not reported.
breast cancer and AML (74). Childs et al. recently re-
ported evidence for a GVt effect in patients with meta-
static renal cell carcinoma (RCC) undergoing nonmye-
loablative stem cell transplantation (NMSCT) (16,75,76).
They observed partial and complete responses 2–7
months after transplantation, preceded by achievement of
full donor T cell chimerism and accompanying GVHD
(16,76).
ROLES OF THE CONDITIONING
REGIMEN
Elimination of host tumor cells
Allogeneic HSCT was first considered to deliver
supralethal doses of chemotherapy and total body irradi-
ation (77,78). The major demonstration of the anti-tumor
efficacy of supralethal chemo-radiotherapy is contributed
by the superiority of autologous HSCT over conventional
chemotherapy in various hematological malignancies
(79–82). However, pretransplant high-dose therapy is un-
able to eradicate the malignancy in many patients. At-
tempts to improve disease-free survival by increasing the
intensity of the conditioning regimen were usually ac-
companied by an increase in transplant-related mortality
(TRM) and overall as well as disease-free survival re-
mained unchanged or worsened (83,84).
Making space for donor cells
Immature progenitor cells occupy defined niches
within the marrow stroma to obtain the necessary sup-
port for proliferation and differentiation (85,86). To al-
low access for donor cells to these niches, it was com-
monly believed that host stem cells must be eradicated
by the conditioning regimen (87). However, Storb et al.
recently demonstrated that the graft itself, most likely
through subclinical GVH reactions, is capable to create
these marrow spaces in the absence of both chemother-
apy and bone marrow irradiation (88).
Eradication of the host’s immune responses
It is necessary to abolish host defense prior to trans-
plantation to avoid immune-mediated graft rejection
caused by alloreactive cytotoxic host lymphocytes or by
HLA-specific antibodies (89). The risk of graft rejection
increases in the case of HLA disparities or prior host pre-
sensitization via administration of multiple blood prod-
ucts before HSCT (89). Both the conditioning regimen
and donor T lymphocytes (and particularly donor CD8
lymphocytes) (90) are implicated in the destruction of the
host immune system. Therefore, TCD of the graft as a
method to prevent GVHD may have deleterious effects
on engraftment (27,91). Unfortunately, the use of more
intensive conditioning regimens also increases organ tox-
icity and infection rates. Recently, the Seattle group dem-
onstrated that optimizing postgrafting immunosuppres-
sion can also control the host-versus-graft (HVG)
reaction (92,93). Thus, contrary to TCD of the graft that
prevents GVHD but increases the risk of graft rejection,
optimal postgrafting immunosuppression reduces both




NMSCT usually results in mixed hematopoietic
chimerism (MC) that can be defined as the presence of
1–95% hematopoietic cells of donor origin (Fig. 1). This
state is characterized by mutual donor-host tolerance (and
thus control of both GVH and HVG reactions without
continued use of immunosuppressive agents) while im-
mune responses against other antigens remain normal.
The mechanisms involved include central thymic dele-
tion of both donor- and host-reactive T cells (because
both donor and host dendritic cells are present in the thy-
mus of mixed chimera) and peripheral tolerance due to
suppressor T cells (94).
Preclinical and clinical data suggest that stable mixed
chimerism may be useful to alleviate clinical symptoms
in genetic diseases such as thalassemia (95,96), sickle cell
disease (97), or congenital immunodeficiencies (98,99),
to control autoreactivity in autoimmune diseases
(100–102), or to prevent graft rejection in organ trans-
plantation (103–105).
The first trials of NMSCT for sickle cell disease are
currently ongoing. Initial results suggest that acute
GVHD may be particularly frequent and severe in this
group of patients (106). Two recent reports have shown
that NMSCT may be an ideal treatment to achieve cures
in congenital immunodeficiencies (98,99). Among 18 pa-
tients treated by these two groups, 14 were alive and well
8–26 months after the transplant despite of 4/14 patients
remaining mixed chimera (98,99).
Several reports have shown that life-threatening au-
toimmune diseases can be stabilized or cured by autolo-
gous HSCT (102,107–109). However, initial failures as
well as relapses are relatively frequent. Several animal
studies as well as some observations in humans suggest
that allogeneic HSCT (after conventional or nonmye-
loablative conditioning) may be more efficient (102,110).
Because of its high toxicity, conventional allogeneic
HSCT has so far been restricted to patients with autoim-
mune disease who developed a coincident hematologic
disorder (102). For others, a nonmyeloablative approach
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of allogeneic HSCT may become particularly useful in
the future.
The potential role of mixed hematopoietic chimerism
in organ transplantation was recently demonstrated by the
Boston group, who reported the induction of renal allo-
graft tolerance by combined kidney and peripheral blood
stem cell (PBSC) transplantation from the same HLA-
identical sibling donor after a nonmyeloablative condi-
tioning regimen in a patient with MM and renal failure
(105). Remarkably, the patient accepted the kidney graft
without any immunosuppression for at least 2 years (94).
For the treatment of hematologic malignancies, mixed
donor chimerism (MC) is not expected to be always cu-
rative (111–114). It is now well demonstrated that MC
is associated with relapse in patients with CML receiv-
ing TCD HSCT (111). More recently, Roman et al. stud-
ied the incidence and the significance of minimal resid-
ual disease and MC in CML patients treated with standard
unmanipulated allogeneic bone marrow transplantation
(BMT) (113). In this study, relapse occurred in 1/39 pa-
tients with full donor chimerism (FC) versus 6/9 patients
with MC (p , 0.0001) (113). Moreover, 3 of the 6 pa-
tients who relapsed experienced low-level MC that was
restricted to T cells while they remained BCR-ABL neg-
ative (113). For those patients with hematologic malig-
nancies, MC can be converted to FC by DLI
(16,23,24,115,116) (Fig. 2).
Assessment of hematopoietic chimerism
The assessment of hematopoietic chimerism requires
more sensitive techniques than conventional cytogenetic
analyses because of the availability of only small num-
bers of dividing cells. The most current techniques are
fluorescent in situ hybridization (FISH) with X- and Y-
specific probes in case of sex-mismatched transplant (14)
and PCR-based assays of polymorphic mini- or mi-
crosatellite markers in case of sex-matched transplant
(16,115,117,118). Other techniques based on restriction
fragment length polymorphism (RFLP) are also used
(15).
The evolution of myeloid and lymphoid chimerism af-
ter nonmyeloablative HSCT may be discordant. Achieve-
ment of full donor T cell chimerism is associated with
disease regression (16). Moreover, the Seattle group re-
cently showed that the level of T-cell chimerism on day
28 predicted for both graft failure and acute GVHD (21),
underlying the importance of lineage-specific chimerism
analysis (Fig. 3).
Nonmyeloablative conditioning regimens 
(NMCR) (Table 2)
Because of its toxicity, conventional allogeneic HSCT
is restricted to younger patients (,55 years for allograft
procedures with HLA-identical siblings and ,50 years
for unrelated donor transplants) without significant organ
impairment. Unfortunately, the majority of malignancies
potentially cured by allogeneic HSCT and for which a
GVL effect has been demonstrated are more frequent in
older patients (Fig. 4). The median age at diagnosis for
CML, AML, MM, and CLL varied from 55 to 65 years
(119). Thus, it may be important to develop less toxic ap-
proaches to allografting that can also be extended to older
patients or patients with pre-existing organ impairment.
In 1997, Giralt et al. (13) reported the engraftment of
HLA-identical allogeneic HSC after nonmyeloablative
chemotherapy based on purine analogs. The rationale for
using purine analogs (fludarabine or 2-CDA) was their
capacity to inhibit the mixed lymphocyte reaction in vitro
and to produce lymphopenia and substantial immuno-
suppression in vivo. Other pilot trials by the same group
confirmed these preliminary results and achieved durable
engraftment and remissions in some patients with AML
(120), CML (18), as well as lymphoid malignancies (15),
with a relatively low TRM. The Jerusalem’s group de-
veloped another nonmyeloablative purine analog-based
protocol combining fludarabine, ATG, and low-dose oral
busulfan (14). This NMCR allowed the achievement of
engraftment and full donor chimerism in the majority of
the patients with a low TRM. However, it should be em-
phasized that many patients included in this study would
be considered eligible for conventional allogeneic HSCT.
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FIG. 2. Conversion of mixed chimerism to full donor
chimerism by DLI. The patient received a CD34-selected graft
from an HLA-identical sibling donor after a nonmyeloablative
conditioning regimen combining cyclophosphamide and flu-
darabine (183). Analysis of his white blood cell chimerism on
day 30 evidenced mixed chimerism. CD8-depleted DLI (black
arrows) were given in incremental doses (10, 50, and 503 106
CD31 cells/kg recipient) on days 40, 80, and 120, respectively,
and achieved full donor chimerism without GVHD.
The feasibility of fludarabine-based nonmyeloablative
transplant protocols has also been confirmed more re-
cently by several others groups (16,17,19,121–124).
In an elegant canine allogeneic transplant model, the
Seattle group demonstrated that stable mixed chimerism
could be achieved using pretransplant low-dose total
body irradiation (TBI) combined with post-grafting im-
munosuppression with a combination of CsA and MMF
and that post-grafting immunosuppression can serve to
control both HVG and GVH reactions (92,93). Complete
chimerism was achieved through DLI. Initial experience
in humans showed the feasibility and safety of this ap-
proach (21,22,93). Moreover, major disease responses
were observed in more than 70% of the patients who had
measurable disease pretransplant and achieved sustained
engraftment (21).
Finally, the Boston’s group demonstrated in a murine
model (125) and then in humans that mixed chimerism
could be induced in HLA-matched (24) or two or three
loci-mismatched (23) allogeneic HSCT by a nonmye-
loablative conditioning regimen combining cyclophos-
phamide, thymic irradiation, and ATG.
Toxicity, TRM, and engraftment
Generally, NMCR are well tolerated, inducing little or
no grade 3–4 toxicity, even in patients older than 65 years
or with concomitant comorbidities (15,126,127). How-
ever, there are important discrepancies among the dif-
ferent studies, due to the intensity of the NMCR used,
the age of the patients, as well as the type of transplant
(sibling versus unrelated, HLA-identical versus mis-
match) (Tables 2 and 3). The 200-day TRM varied from
4% in the Seattle study (21) (using low-dose TBI alone
as conditioning regimen in HLA-identical sibling trans-
plants) to 37% in the Houston’s study (18) (using mel-
phalan and purine analog-containing preparative regi-
mens in related or unrelated graft recipients ineligible for
conventional transplants). In the EBMT study reporting
on 256 NMSCT for various hematologic malignancies,
the 1-year probability of TRM was 13% for patients in
CR at the time of transplant versus 36% for patients in
more advanced disease (128). Moreover, age was also
significantly associated with TRM in some studies (20).
The primary causes of nonrelapse mortality in 4 major
studies are given in Table 4.
The engraftment rate was also related to the intensity
of the NMCR as well as the type of transplant. Gener-
ally, more intensive conditioning regimens resulted in
higher engraftment rates:graft failure rates ranged from
0% to 20% of the cases in the Jerusalem study and in the
Seattle study, respectively (14,21). Moreover, the im-
mune status of the recipient also appeared to be impor-
tant for engraftment. For example, a high incidence of
graft rejection was observed by the Seattle group in pre-
viously untreated CML patients (129), inducing them to
add fludarabine in their “TBI only” protocol for such pa-
tients.
Acute and chronic GVHD
In both animal and human studies, the use of less se-
vere conditioning (130,131), as well as the initial pres-
ence of host hematopoietic cells (132,133), decreased the
severity of acute GVHD. These observations predict that
acute GVHD may be reduced by the use of NMCR be-
cause of their low intensity and the high incidence of
mixed chimerism achieved.
Indeed, preliminary data suggest that acute GVHD is
relatively mild and generally controllable after NMCR
(21,120). Moreover, acute GVHD is usually delayed and
BARON AND BEGUIN
248
FIG. 3. Illustration of the influence of the underlying disease
and previous therapy on engraftment after a nonmyeloablative
conditioning regimen consisting of 2 Gy TBI alone. (A) T cell
(CD3) and myeloid (CD13) chimerism in a patient transplanted
for chronic-phase CML. (B) T cell (CD3) and myeloid (CD13)
chimerism in a patient transplanted for poor-prognosis Hodg-


















































































































































































































































































































































































































































































































































































































































































































































































occurs after patients have recovered from conditioning-
related toxicities (16,21). However, there are relatively
large discrepancies among the different studies. This vari-
ability probably relates to differences in the source of
stem cells (bone marrow versus PBSC), type of trans-
plant (related versus unrelated), GVHD prophylaxis, use
of ATG, as well as age of the patient. However, acute
GVHD is still the leading cause of nonrelapse mortality
(Table 4).
The optimal type and duration of post-transplant im-
munosuppressive therapy are uncertain. After conven-
tional transplantation, high-dose immunosuppressive
therapy given soon after HSCT to prevent GVHD also
increases the risk of relapse (134). On the other hand, the
French study recently evidenced a significant influence
of GVHD prophylaxis on overall survival (better with
longer prophylaxis) and TRM (higher with shorter pro-
phylaxis) after NMSCT (123).
Additional DLI are significantly associated with in-
creased risks of both GVHD (24) and TRM (123). How-
ever, the time of infusion as well as the dose of lym-
phocytes given play a major role. This is illustrated by
the observation of powerful GVL effects without signif-
icant GVHD of single DLI of 107 CD31 cells/kg given
on day 35, contrasting with the high incidence of severe
acute GVHD after repeated DLI on days 35 and 56 (24).
Because of short follow-up, the incidence and sever-
ity of chronic GVHD is still uncertain. However, pre-
liminary trials reported the occurrence of severe chronic
GVHD in some cases (15). Moreover, despite such short
follow-up, the risk of chronic GVHD was already 74%
in the Seattle’s study (21) and 68% in the Houston’s re-
port (18).
Antitumor efficacy
Although data are too early to assess antitumor effects
definitively, preliminary results clearly demonstrated the
occurrence of major disease responses in patients with
hematological as well as some solid tumors.
CLL and lymphoma: Durable complete responses were
observed in several patients with refractory non-Hodg-
kin’s lymphoma (NHL), Hodgkin’s disease (HD), or CLL
(15,23,135). The Boston group reported the evolution of
16 patients treated with NMSCT after a conditioning reg-
imen combining cyclophosphamide, ATG, and thymic ir-
radiation for refractory NHL, HD, or CLL. Complete re-
sponses were observed in 7/16 patients (4/11 patients
with NHL, 2/3 patients with HD, and 1/2 patients with
CLL). Similarly, the Jerusalem group reported on a group
of 23 heavily treated high-risk malignant lymphomas
(136). Ten of the 23 patients were alive in CR 15–37
months after the transplant and the 3-year probability of
disease-free survival was 40%. Kottaridis et al. reported
on 13 patients with HD or NHL in partial remission or
with refractory disease (17). The NMCR consisted of flu-
darabine, melphalan, and CAMPATH-1H. Four out of
the 13 patients experienced a complete response, and sta-
bilization occurred in 7 other patients. However, in a ret-
rospective study of 115 lymphoma patients (most of them
receiving an HLA-identical sibling transplant after a flu-
darabine-based NMCR), the EBMT encountered a 38%
rate of TRM at 1 year, mostly due to a high incidence of
severe GVHD (137).
CML: Complete cytogenetic or molecular remissions
were obtained in more than 75% CML patients trans-
planted in chronic phase (16–18,21,138) (Table 5). More-
over, some patients with more advanced-phase disease
also achieved molecular remission (21,124). The EBMT
recently summarized the results of 58 CML patients, most
of them receiving an HLA-identical sibling transplant af-
ter a fludarabine-based NMCR (139). The overall 1-year
survival was 87% for patients grafted in first chronic
phase (n 5 32) versus 58% for patients transplanted in
more advanced phase. The 1-year disease-free survivals
were 75% and 46%, respectively.
Multiple myeloma: Durable (.1 year) partial and com-
plete responses were also observed in some patients with
MM (17,21,140). Badros et al. (140) studied 16 MM pa-
tients receiving a NMSCT after conditioning with mel-
phalan 100 mg/m2. After a median follow-up of 1 year,
5 patients achieved and sustained CR, 3 near CR, and 4
partial response (PR). Two patients died of progressive
disease and 3 died of GVHD without active disease. The
EBMT retrospectively collected data from 54 patients
who received NMSCT for good- (CR, PR1, or PR2, n 5
36) or poor- (n 5 18) risk MM. (141). In this study, the
1-year rates of survival, TRM, and relapse for the good-
risk group were 83%, 13%, and 11%, respectively. The
figures were 25%, 68%, and 20% for poor-risk patients.
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FIG. 4. Age distribution of patients diagnosed with CML (d )
























































































































































































































































































































































































































































































































































































































































































































































AML, ALL, and MDS: Storb recently reported the re-
sults of 17 AML patients treated with related NMSCT
after conditioning with 2 Gy TBI 6 fludarabine (90
mg/m2) (22). Eight of 10 patients grafted in CR remained
in CR after 5–18 months. Moreover, 2/3 patients with
primary refractory disease were in remission at more than
20 months. Prolonged remissions in refractory AML pa-
tients were also reported by other groups (18,138). The
EBMT recently reported data on 154 patients treated with
NMSCT for AML, ALL, or MDS (142). For AML pa-
tients in CR1 or CR2, the 1-year actuarial overall sur-
vival, TRM, and relapse rates were 67%, 17%, and 21%,
respectively, compared to 24%, 68%, and 46% for pa-
tients in more advanced disease (142). For ALL patients,
the figures were 15%, 72%, and 55%, respectively, and
results in CR1-2 were the same as in more advanced dis-
ease, suggesting that, in contrast with AML patients, ALL
patients did not benefit from NMSCT (142). Finally, in
the same study, 3/3 patients with refractory anemia sur-
vived in CR more than 1 year after transplant and pa-
tients with more advanced MDS experienced 48% TRM
and 33% relapse rates at 1 year (142).
Solid tumors: In patients with solid tumors, responses
were partial and transient in patients with breast cancer
(143,144) or melanoma (16,145), whereas some patients
with RCC achieved durable complete responses
(16,75,76).
Childs et al. has recently reported the evolution of 19
patients treated with NMSCT after conditioning with flu-
darabine and cyclophosphamide for metastatic RCC (76).
Ten of the 19 patients enjoyed major responses, includ-
ing 3 patients with sustained (.20 months) complete re-
sponse. These responses occurred 3–6 months after the
transplant and usually after cyclosporine discontinuation.
Acute GVHD was associated with disease response but,
interestingly, one patient had a complete response in the
absence of acute GVHD (76).
The same group explored the same NMSCT approach
in 15 patients with advanced metastatic melanoma (145).
Four of the 15 patients had partial responses that occurred
soon after transplant (before CsA withdrawal and before
the development of acute GVHD), suggesting that these
responses were related to the conditioning regimen rather
than to a GVt effect. All other patients progressed. Sur-
face analysis of renal and melanoma tumor cell lines ob-
tained from transplanted patients evidenced that most of
the RCC cells expressed MHC class I, whereas several
lines obtained from melanoma patients did not (Barrett
et al., EBMT 2001, educational book). This finding could
partially explain the lack of sensitivity of melanoma cells
to the GVt effect. However, other mechanisms of tumor
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Author of transplants GVHD Toxicity Infection Other
Giralt (18) 29/86 16 (55) 3 (10) 9 (31) 1 (3)
McSweeney (21) 7/45 4 (57)a 0 (0) 3 (43) 0 (0)
Sykes (24) 2/21 2 (100)a 0 (0) 0 (0) 0 (0)
Lalancette (128) 32/115 18 (56) 5 (16) 9 (28) 0 (0)
Total 70/267 40 (57) 8 (11) 21 (30) (1)
aAfter DLI.
Causes of death: number (%)
TABLE 5. RESULTS IN CHRONIC-PHASE CML
Number Number of patients Number of patients
Author (reference) of patients with CCR with graft rejection
McSweeney (21) 6 4 2
Giralt (18) 5 2 1
Kottaridis (17) 1 1 0
Barrett (16) 3 2 1
Slavin (182) 21 19 0
Total 36 28 4
CCR, continuous CR.
escape from immune destruction, including the loss of
adhesion or costimulatory molecules, secretion of in-
hibitory cytokines or expression of fas ligand, may also
probably play a major role in the NMSCT setting
(146,147).
Secondary malignancies after autologous or allo-
geneic HCT: Treatment options for patients who relapse
or develop secondary malignancies after autologous or
allogeneic HCT are limited. In these patients, results of
a second alloHSCT are generally poor, primarily because
of a high rate of TRM. Recently, the Jerusalem group
studied the feasibility of a second allogeneic HSCT after
a nonmyeloablative conditioning regimen (148). Among
the 12 patients included, only one died of procedure-re-
lated complications, suggesting that NMCR significantly
reduce TRM associated with second transplants. More-
over, the actuarial disease-free survival at 34 months was
50%. These findings were confirmed by Kottaridis et al.,
who reported a 14% TRM associated with an allogeneic
NMSCT for disease relapses occurring after standard au-
tologous or allogeneic HSCT (17).
Autologous HSCT followed by NMSCT: Previous at-
tempts of immunotherapy after autologous HSCT by in-
duction of autologous GVHD (149,150) or by interleukin
(IL-2) (151) did not show significant antitumor efficacy.
For patients with a high tumor burden, the Genoa’s group
studied the feasibility of conventional autologous HSCT
followed by NMCST 1–3 months later (121) (Fig. 5). The
rationale for high-dose therapy followed by autologous
HSCT was debulking and the rationale for NMSCT was
to induce immune-mediated antitumor effects. The ratio-
nale for separating high-dose therapy from allogeneic
transplantation was to reduce the TRM and the risk of
acute GVHD (see above). Preliminary results evidenced
the feasibility of this approach with a low TRM
(121,144,152).
PERSPECTIVES
Manipulation of donor cells to separate the GVL
effect from GVHD
Escalating doses of DLI: It is well demonstrated that
the risk of GVHD correlates with the dose of lympho-
cytes infused (8,33,46). In an elegant article, Mackinnon
et al. (46) showed that it was possible to reduce the risk
of GVHD without impairing the GVL effect by starting
with a low dose of T cells and increasing the dose in a
stepwise fashion in case of no response. Their observa-
tions were recently confirmed by another study that com-
pared the efficacy and safety of a single infusion of rel-
atively large doses of donor lymphocytes (bulk dose
regimen, BDR) versus infusion of smaller doses repeated
as necessary at 3-month intervals (escalating dose regi-
men, EDR) in CML patients relapsing after conventional
allografting (47). The CR rate at 2 years was higher (but
not statistically significant) and the risk of both acute and
chronic GVHD was significantly lower in patients allo-
cated to the EDR regimen, even when the total number
of cells administered was similar. This approach is cur-
rently investigated in the NMSCT setting.
CD8-depletion of the graft and/or DLI: Contrary to
pan T cell depletion of donor marrow that increases the
risk of relapse (particularly in patients with CML), se-
lective CD81 T cell depletion of the graft significantly
reduces the risk of GVHD without affecting the GVL ef-
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FIG. 5. The Genoa approach. Schedule of high-dose therapy and autologous HSCT followed by moderate immunosuppression
and allogeneic NMSCT.
fect (153,154). Similarly, several studies demonstrated
that CD8-depletion of therapeutic DLI (44,59,155) re-
duces the risk of DLI-induced GVHD without impairing
the GVL effect. The potential role of CD8-depletion
should be examined in NMSCT.
T cell depletion of the graft followed by T cell add-
back: It is now well demonstrated that a conditioning reg-
imen-related cytokine storm plays a major role in the
pathogenesis of GVHD (156). Moreover, in the NMSCT
setting, it is well demonstrated that donor lymphocytes
given several weeks after the transplant in mixed chimera
induce significantly less GVHD than a similar dose of
donor T cells given together with the transplant, without
reducing their antitumor efficacy (125). Recently, we
have reported that transplantation of CD34-selected al-
logeneic PBSC after a myeloablative preparative regimen
followed by pre-emptive CD8-depleted DLI significantly
decreases the incidence of acute and severe chronic
GVHD as compared with unmanipulated BMT (157). We
also investigated the feasibility and efficacy of NMSCT
with CD8-depleted or CD34-selected PBSC followed by
pre-emptive CD8-depleted DLI given in incremental
doses on days 40 and 80 (depleted group). None of the
10 patients included in the depleted group versus 3/4 re-
cipients of unmanipulated PBSC and DLI experienced
grade II–IV acute GVHD. Most of the patients included
in the depleted group were mixed chimera on day 30 but
became full-donor chimera after CD8-depleted DLI (Fig.
2).
In vivo T cell depletion using CAMPATH-1H: Kot-
taridis et al. (17) recently investigated a novel nonmye-
loablative conditioning regimen consisting in CAM-
PATH-1H, fludarabine (150 mg/m2) and melphalan (140
mg/m2). They observed a high engraftment rate (.97%),
but most of the patients analyzed were mixed chimera.
The incidence of GVHD was exceptionally low (5% of
grade II–IV acute GVHD) (Table 3). The authors explain
this observation by the use of in vivo CAMPATH-1H
(achieving in vivo T cell depletion of the graft because
of its prolonged half-life in humans) and by the high in-
cidence of mixed chimerism (known to reduce the inci-
dence and severity of GVHD) (133). However, because
mixed chimerism may diminish the GVL effect seen in
the allograft setting, longer follow-up is needed to clar-
ify whether this approach respects the GVL effect.
Infusion of donor lymphocytes transfected with a sui-
cide gene: Another interesting approach consists in in
vitro insertion of a suicide gene, the herpes simplex virus
thymidine kinase (HSV-tk) gene, which selectively phos-
phorylates gancyclovir (GCV) leading to its incorpora-
tion into DNA and causing cell death into lymphocytes,
and allowing their selective elimination by GCV if se-
vere GVHD develops after DLI (158–160). A first clin-
ical study using this approach demonstrated antitumor re-
sponses and efficient elimination of infused cells by GCV
in case of GVHD (159). Unfortunately, induction of a
strong immune response against genetically modified
cells and partial resistance to ganciclovir-mediated elim-
ination of transduced cells in chronic GVHD were ob-
served (161,162). Another trial of 23 patients (14 with
CML) was recently reported (163). No toxicity or GVHD
was observed even with cumulative doses .2 3 108
CD3/kg recipient. However, only 2 patients (2 with CML)
achieved CR, suggesting that the GVL effect was im-
paired by the transduction procedure. Whether this ap-
proach will be applicable in the nonmyeloablative setting
remains to be determined.
Infusion of tumor-specific CTL: Donor-derived CTL
have been used successfully for the treatment of cy-
tomegalovirus (CMV) infections (164) or for the pre-
vention or treatment of Epstein-Barr virus (EBV)-asso-
ciated lymphoma after allogeneic HSCT (165).
Remarkably, no significant toxicity nor GVHD were ob-
served with this early post-transplant cell immunother-
apy. Recently, the Leiden’s group reported the achieve-
ment of CR in a patient with accelerated-phase CML by
treatment with leukemia-reactive CTL (35). The infusion
of donor-derived specific CTL against specific antigens
such as mHA preferentially expressed in hematopoietic
system (166,167), tumor-specific antigens (168,169), or
antigens overexpressed in tumor cells, such as proteinase
3 (66–68) or WT-1 (69), all represent promising meth-
ods of immune cell therapy. Combining these approaches
with CD8-depletion, CD34-selection, or other forms of
in vitro TCD or with the use of in vivo CAMPATH-1H
in the future may permit to increase the GVL effect while
minimizing the risk of GVHD after NMSCT.
Combination of NMSCT with other approaches
Recombinant human (rh) IL-2 or interferon-a in con-
junction with DLI: Several approaches have been devel-
oped to increase the efficacy of DLI (170). First, Slavin
et al. showed that rhIL-2 activated DLI can induce CR
in several patients with hematologic malignancies re-
fractory to unmanipulated DLI (171,172). In RCC, Childs
et al. have demonstrated that interferon-a (IFN-a) could
increase the antitumor effect of DLI, even in patients pre-
viously refractory to IFN-a (76).
Combination of STI-571 and NMSCT/DLI: STI-571 is
a specific inhibitor of the BCR-ABL tyrosine kinase
(173). Preliminary results indicate that STI-571 induces
complete cytogenetic responses in the majority of CML
patients in the chronic phase as well as in some patients
with CML in blast crisis or Phi-positive acute leukemia
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(174–176). Unfortunately, responses were often transient,
and resistance to STI-571 occurred in the majority of pa-
tients with blast crisis or Phi-positive acute leukemia
(176–178). Because the outcome of DLI is better in early-
phase CML than in more advanced relapse, prior reduc-
tion of marrow blasts may be an useful step before 
NMSCT or before DLI for CML in blast crisis or for Phi-
positive acute leukaemia. Recently, we have reported the
successful treatment by STI-571 and DLI of Phi-chro-
mosome positive acute leukaemia relapsing after a stan-
dard unrelated HSCT (179). Similarly, Olavarria et al. re-
cently showed that STI-571 alone could induce mixed
chimerism in CML patients relapsing in blast crisis after
allogeneic HSCT (180). Taken together, these obser-
vations suggest that the combination of STI-571 and 
NMSCT may be an effective strategy for CML blast cri-
sis patients.
CONCLUSION
In conclusion, NMSCT is feasible and can lead to mo-
lecular responses. This transplant strategy offers several
advantages over conventional HSCT: (1) TRM is re-
duced; (2) acute GVHD could be less frequent and less
severe than after myeloablative HSCT; and (3) NMSCT
is possible in patients older than 55 or with concomitant
comorbidities. Further clinical trials are needed to define
more effective strategies to separate GVL effects from
GVHD and to compare the relative efficacy of this ap-
proach to conventional treatment. Because the benefits
of NMSCT over alternative forms of treatment remain to
be demonstrated, this strategy should be restricted to pa-
tients included in clinical trials.
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